References
Choi JY, Glasauer S, Kim JH, Zee DS, Kim JS (2018) Characteristics and mechanism of apogeotropic central positional nystagmus. Brain 141:762–775
Gomez CM, Thompson RM, Gammack JT, Perlman SL, Dobyns WB, Truwit CL, Zee DS, Clark HB, Anderson JH (1997) Spinocerebellar ataxia type 6: gaze-evoked and vertical nystagmus, Purkinje cell degeneration, and variable age of onset. Ann neurol 42:933–950
Hebron ML, Lonskaya I, Moussa CEH (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of -synuclein in Parkinsons disease models. Hum Mol Genet 22:3315–3328
Jacobi H, Bauer P, Giunti P, Labrum R, Sweeney MG, Charles P, Durr A, Marelli C, Globas C, Linnemann C, Schols L, Rakowicz M, Rola R, Zdzienicka E, Schmitz-Hubsch T, Fancellu R, Mariotti C, Tomasello C, Baliko L, Melegh B, Filla A, Rinaldi C, van de Warrenburg BP, Verstappen CC, Szymanski S, Berciano J, Infante J, Timmann D, Boesch S, Hering S, Depondt C, Pandolfo M, Kang JS, Ratzka S, Schulz J, Tezenas du Montcel S, Klockgether T (2011) The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology 77:1035–1041
Klockgether T, Mariotti C, Paulson HL (2019) Spinocerebellar ataxia. Nat Rev Dis Primers 5:24
Lee WJ, Moon J, Kim TJ, Jun JS, Lee HS, Ryu YJ, Lee ST, Jung KH, Park KI, Jung KY, Kim M, Lee SK, Chu K (2017) The c-Abl inhibitor, nilotinib, as a potential therapeutic agent for chronic cerebellar ataxia. J Neuroimmunol 309:82–87
Lindholm D, Pham DD, Cascone A, Eriksson O, Wennerberg K, Saarma M (2016) c-Abl inhibitors enable insights into the pathophysiology and neuroprotection in Parkinson’s disease. Front Aging Neurosci 8:254
Pagan F, Hebron M, Valadez EH, Torres-Yaghi Y, Huang X, Mills RR, Wilmarth BM, Howard H, Dunn C, Carlson A, Lawler A, Rogers SL, Falconer RA, Ahn J, Li Z, Moussa C (2016) Nilotinib effects in parkinson’s disease and dementia with lewy bodies. J Parkinsons Dis 6:503–517
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, Investigators EN (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251–2259
Schlatterer SD, Acker CM, Davies P (2011) c-Abl in neurodegenerative disease. J Mol Neurosci 45:445–452
Sullivan R, Yau WY, O’Connor E, Houlden H (2019) Spinocerebellar ataxia: an update. J Neurol 266:533–544
Turner RS, Hebron ML, Lawler A, Mundel EE, Yusuf N, Starr JN, Anjum M, Pagan F, Torres-Yaghi Y, Shi W, Mulki S, Ferrante D, Matar S, Liu X, Esposito G, Berkowitz F, Jiang X, Ahn J, Moussa C (2020) Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer’s disease. Ann Neurol 88:183–194
Wang X, Wang H, Xia Y, Jiang H, Shen L, Wang S, Shen R, Xu Q, Luo X, Tang B (2010) Spinocerebellar ataxia type 6: Systematic patho-anatomical study reveals different phylogenetically defined regions of the cerebellum and neural pathways undergo different evolutions of the degenerative process. Neuropathology 30:501–514
Zhou Y, Yamamura Y, Ogawa M, Tsuji R, Tsuchiya K, Kasahara J, Goto S (2018) c-Abl inhibition exerts symptomatic antiparkinsonian effects through a striatal postsynaptic mechanism. Front Pharmacol 9:1311
Acknowledgements
None.
Funding
None.
Author information
Authors and Affiliations
Contributions
Dr. S.Y. Choi conducted the experiments, analyzed and interpreted the data, and wrote the manuscript. Drs. K.D. Choi and H.J. Kim analyzed and interpreted the data.
Prof. J.S. Kim conducted the design and conceptualization of the study, interpretation of the data, and revised the manuscript.
Corresponding author
Ethics declarations
Conflicts of interest
Drs. S.Y. Choi, K.D. Choi, and H.J. Kim report no disclosure. Prof. J.S. Kim serves as an associate editor of Frontiers in Neuro-otology and on the editorial boards of the Journal of Clinical Neurology, Frontiers in Neuro-ophthalmology, Journal of Neuro-ophthalmology, Journal of Vestibular Research, Journal of Neurology, Medicine, and Clinical and Translational Neuroscience.
Ethical standard
This study followed the tenets of the Declaration of Helsinki, and was performed according to the guidelines of Institutional Review Board of Pusan National University Hospital (1907–006-080). Signed patient consent-to-disclose forms were also obtained.
Rights and permissions
About this article
Cite this article
Choi, SY., Kim, HJ., Choi, KD. et al. Efficacy of nilotinib in monozygotic twins with spinocerebellar ataxia type 6. J Neurol 269, 2769–2773 (2022). https://doi.org/10.1007/s00415-021-10895-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-021-10895-x